| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Neurokinin-3 (NK3) receptor (selective antagonist).
|
|---|---|
| ln Vitro |
In U-2OS cells expressing the human NK3 receptor, talnetant (SB 223412) (0.1–1 μM) hydrochloride decreases NKB-induced IP accumulation [3].
Talnetant hydrochloride is a selective, competitive NK3 receptor antagonist with a Ki of 1.4 nM in hNK-3-CHO cells. It shows 100-fold selectivity for hNK-3 over hNK-2 receptor and has no affinity for hNK-1 at concentrations up to 100 μM. The compound is brain-permeable and suitable for CNS research. |
| ln Vivo |
Talnetant (SB 223412) hydrochloride (0.5-2 mg/kg iv, 2 min pre-treatment) suppresses the dose-dependent induction of miosis in conscious rabbits by senktide (25 μg, iv) with an ED50 of 0.44 mg/kg [1]. Senktide-induced "wet dog wag" behavior can be considerably attenuated in a dose-dependent manner by tanetant (SB 223412) hydrochloride (i.p., 1-100 mg/kg, 1 h), which also dramatically increases the number of cells in the medial prefrontal cortex. In the vomeronasal nucleus of freely moving guinea pigs, external dopamine and norepinephrine were found to decrease haloperidol-induced elevations in dopamine levels [3].
No specific in vivo efficacy data are available for Talnetant hydrochloride. As a brain-permeable NK3 receptor antagonist, it would be expected to modulate neurokinin signaling in vivo and potentially produce anxiolytic or antipsychotic-like effects, but no published animal study results are currently documented. |
| Enzyme Assay |
The binding assay for NK3 receptor antagonists uses membranes from hNK-3-CHO cells or recombinant cells expressing NK3 receptor. Radiolabeled neurokinin B or a selective NK3 agonist is used as a tracer. Test compounds compete for binding, and Ki values are determined from competition curves.
|
| Cell Assay |
In cellular assays, cells expressing recombinant NK3 receptor are treated with Talnetant hydrochloride. Receptor activation is assessed by measuring intracellular calcium mobilization or inositol phosphate production. IC50 values for inhibition of agonist-induced signaling are calculated to confirm antagonist activity.
|
| Animal Protocol |
Animal/Disease Models: Male Dunkin-Hartley guinea pig [3]
Doses: 1, 3, 10, 30 or 100 mg/kg Route of Administration: intraperitoneal (ip) injection; 1 hour Experimental Results: Wet dog shake (WDS) at 30 mg/kg Behavior weakened Dramatically, falling from 31.1 to 16.7. Extracellular DA levels were Dramatically increased to 238%, and NE levels were Dramatically increased to 227.1%, without affecting 5-HT levels. No specific in vivo animal study protocols are documented for Talnetant hydrochloride. General models of anxiety, schizophrenia, or pain could be used, with the compound administered systemically, and behavioral and physiological endpoints assessed to evaluate therapeutic potential. |
| References |
|
| Molecular Formula |
C25H22N2O2.HCL
|
|---|---|
| Molecular Weight |
418.91532
|
| Exact Mass |
418.145
|
| CAS # |
204519-66-4
|
| Related CAS # |
Talnetant;174636-32-9
|
| PubChem CID |
9844955
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
580.4ºC at 760 mmHg
|
| Flash Point |
304.8ºC
|
| Vapour Pressure |
4.51E-14mmHg at 25°C
|
| LogP |
6.865
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC1=C(C(N[C@H](C2=CC=CC=C2)CC)=O)C3=C(N=C1C4=CC=CC=C4)C=CC=C3.[H]Cl
|
| InChi Key |
BHCSUEHQURQVLD-BDQAORGHSA-N
|
| InChi Code |
InChI=1S/C25H22N2O2.ClH/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18;/h3-16,20,28H,2H2,1H3,(H,27,29);1H/t20-;/m0./s1
|
| Chemical Name |
3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3871 mL | 11.9355 mL | 23.8709 mL | |
| 5 mM | 0.4774 mL | 2.3871 mL | 4.7742 mL | |
| 10 mM | 0.2387 mL | 1.1935 mL | 2.3871 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
